Skip to main content

Table 2 Bayesian Analysis of ADCOMS at 12 months—full analysis set

From: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

 

Change from baseline

Posterior quantities*

Treatment group

Total N

Mean

SD

Pr (Max)

Pr (ED90)

Pr Superiority

Pr (CSD)

ADCOMS—overall

 Placebo control

229

0.113

0.012

 2.5 mg/kg biweekly

51

0.134

0.024

0.009

0.009

0.216

0.028

 5 mg/kg monthly

48

0.119

0.021

0.022

0.031

0.416

0.070

 5 mg/kg biweekly

87

0.116

0.016

0.010

0.010

0.446

0.053

 10 mg/kg monthly

242

0.084

0.011

0.318

0.386

0.961

0.479

 10 mg/kg biweekly

143

0.077

0.014

0.642

0.563

0.976

0.638

  1. Only subjects with non-missing data at both baseline and the relevant post-baseline visit are included in the change from baseline summary statistics
  2. ADCOMS, Alzheimer’s Disease Composite Score; CSD, clinically significant difference; 25% better than placebo, ED90, dose regimen with at least 90% of the dmax treatment effect; Max, maximum treatment effect; Pr, probability; Pr (Max), probability of being maximal effective dose; Pr (ED90), probability of being the ED90 dose; Pr (Superiority), probability to be superior to placebo by any magnitude; Pr (CSD), probability to be better than placebo by at least 25%
  3. *Probabilities can be interpreted as a percentage (e.g., 0.10 is 10%)